부산대학교 도서관

Background While both the burden of therapy and the individual drugs in bictegravir/tenofovir alafenamide/emtricitabine (BIC/TAF/FTC) and dolutegravir/lamivudine differ, it is unclear whether their real-life tolerability may be also different. Methods Single-centre, clinical cohort analysis of all virologically suppressed persons with HIV (PWH) who were first prescribed bictegravir as BIC/TAF/FTC or dolutegravir as dolutegravir/lamivudine and had taken ≥1 dose of study medication. Major outcomes were discontinuations either for any reason or due to toxicity. Incidence was calculated as number of episodes per 100 person-years adjusted through propensity score analysis. Results Relative to persons treated with BIC/TAF/FTC (n  = 1231), persons treated with dolutegravir/lamivudine (n  = 821) were older and had more AIDS-defining conditions although better HIV control. After a median follow-up of 52 weeks, adjusted incidence rates for discontinuation were 6.68 (95% CI 5.18–8.19) and 8.44 (95% CI 6.29–10.60) episodes per 100 person-years for BIC/TAF/FTC and dolutegravir/lamivudine, respectively; adjusted incidence rate ratio for dolutegravir/lamivudine was 1.26 (95% CI 0.89–1.78) relative to BIC/TAF/FTC (P  = 0.1847). Adjusted incidence rates for discontinuation due to toxicity were 3.88 (95% CI 2.70–5.06) and 4.62 (95% CI 3.05–6.19) episodes per 100 person-years for BIC/TAF/FTC and dolutegravir/lamivudine, respectively; adjusted incidence rate ratio for dolutegravir/lamivudine was 1.19 (95% CI 0.75–1.90) relative to BIC/TAF/FTC (P  = 0. 4620). Adverse events leading to discontinuation were neuropsychiatric (n  = 42; 2%), followed by gastrointestinal (n  = 23; 1%), dermatological (n  = 15; 1%) and weight increase (n  = 15; 1%), without differences between regimens. Conclusions Switching to BIC/TAF/FTC or dolutegravir/lamivudine showed no difference in the risks of overall or toxicity-related discontinuations or in the profile of adverse events leading to discontinuation. [ABSTRACT FROM AUTHOR]